• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Arch Virol . The emerging role of probiotics as a mitigation strategy against coronavirus disease 2019 (COVID-19)

tetano

Editor, Senior Moderator
Arch Virol


. 2021 Mar 20.
doi: 10.1007/s00705-021-05036-8. Online ahead of print.
The emerging role of probiotics as a mitigation strategy against coronavirus disease 2019 (COVID-19)


Rasoul Mirzaei[SUP] 1 2 [/SUP], Adeleh Attar[SUP] 3 [/SUP], Saher Papizadeh[SUP] 4 [/SUP], Ali Salimi Jeda[SUP] 5 [/SUP], Seyed Reza Hosseini-Fard[SUP] 6 [/SUP], Elaheh Jamasbi[SUP] 7 [/SUP], Sima Kazemi[SUP] 1 [/SUP], Saman Amerkani[SUP] 4 [/SUP], Gholam Reza Talei[SUP] 8 [/SUP], Pouya Moradi[SUP] 9 [/SUP], Saba Jalalifar[SUP] 10 [/SUP], Rasoul Yousefimashouf[SUP] 1 11 [/SUP], Mohammad Akhter Hossain[SUP] 12 [/SUP], Hossein Keyvani[SUP] 13 14 [/SUP], Sajad Karampoor[SUP] 15 16 [/SUP]



Affiliations

Abstract

COVID-19 is an acute respiratory infection accompanied by pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has affected millions of people globally. To date, there are no highly efficient therapies for this infection. Probiotic bacteria can interact with the gut microbiome to strengthen the immune system, enhance immune responses, and induce appropriate immune signaling pathways. Several probiotics have been confirmed to reduce the duration of bacterial or viral infections. Immune fitness may be one of the approaches by which protection against viral infections can be reinforced. In general, prevention is more efficient than therapy in fighting viral infections. Thus, probiotics have emerged as suitable candidates for controlling these infections. During the COVID-19 pandemic, any approach with the capacity to induce mucosal and systemic reactions could potentially be useful. Here, we summarize findings regarding the effectiveness of various probiotics for preventing virus-induced respiratory infectious diseases, especially those that could be employed for COVID-19 patients. However, the benefits of probiotics are strain-specific, and it is necessary to identify the bacterial strains that are scientifically established to be beneficial.
 
Back
Top Bottom